Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022010319 - FUSION PROTEIN INCLUDING GLUCAGON-LIKE PEPTIDE-1 AND INTERLEUKIN-1 RECEPTOR ANTAGONIST AND USE THEREOF

Publication Number WO/2022/010319
Publication Date 13.01.2022
International Application No. PCT/KR2021/008824
International Filing Date 09.07.2021
IPC
C07K 14/605 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
605Glucagons
C07K 14/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C12N 15/62 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
A61K 38/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 3/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
Applicants
  • (주)지아이이노베이션 GI INNOVATION, INC. [KR]/[KR]
Inventors
  • 장명호 JANG, Myoung Ho
  • 남수연 NAM, Su Youn
  • 조영규 CHO, Young-Gyu
  • 오영민 OH, Young Min
  • 오나현 OH, Nahyun
  • 임혜진 LIM, Hyejin
Agents
  • 류종우 RYU, Jong Woo
  • 이내영 LEE, Rae Young
Priority Data
10-2020-008535510.07.2020KR
Publication Language Korean (ko)
Filing Language Korean (KO)
Designated States
Title
(EN) FUSION PROTEIN INCLUDING GLUCAGON-LIKE PEPTIDE-1 AND INTERLEUKIN-1 RECEPTOR ANTAGONIST AND USE THEREOF
(FR) PROTÉINE DE FUSION COMPRENANT UN PEPTIDE-1 DE TYPE GLUCAGON ET UN ANTAGONISTE DE RÉCEPTEUR DE L'INTERLEUKINE-1 ET UTILISATION ASSOCIÉE
(KO) 글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 융합단백질 및 이의 용도
Abstract
(EN) The present invention relates to a fusion protein dimer including glucagon-like peptide-1 (GLP-1) and interleukin-1 receptor antagonist (IL-1Ra) and a pharmaceutical composition using same for treating metabolic diseases. In addition to acting significantly as a GLP-1 hormone, the fusion protein dimer was also identified to bind effectively to an IL-1 receptor to excellently inhibit the signaling to IL-1β produced by inflammasome. Therefore, the fusion protein dimer according to the present invention exhibits the efficacies of GLP-1 and IL-1 receptor antagonist in combination and as such, can be utilized for treating and preventing metabolic diseases such as diabetes mellitus, obesity, and hyperlipidemia, finding high industrial applicability.
(FR) La présente invention concerne un dimère de protéine de fusion comprenant un peptide-1 de type glucagon (GLP-1) et un antagoniste de récepteur de l'interleukine-1 (IL-1Ra) et une composition pharmaceutique l'utilisant pour le traitement de maladies métaboliques. En plus d'agir significativement comme une hormone GLP-1, le dimère de protéine de fusion a également été identifié comme se liant efficacement à un récepteur d'IL-1 pour inhiber de manière excellente la signalisation à IL-1ß produite par l'inflammasome. Par conséquent, le dimère de protéine de fusion selon la présente invention présente les efficacités de GPL-1 et de l'antagoniste du récepteur d'IL-1 en combinaison et, en tant que tel, peut être utilisé pour traiter et prévenir des maladies métaboliques telles que le diabète sucré, l'obésité et l'hyperlipidémie, en trouvant de nombreuses applications industrielles.
(KO) 본 발명은 글루카곤-유사 펩타이드-1(GLP-1) 및 인터루킨-1 수용체 길항제(IL-1Ra)를 포함하는 융합단백질 이량체 및 이를 이용한 대사성 질환 치료용 약학 조성물에 관한 것이다. 상기 융합단백질 이량체가 GLP-1 호르몬으로서 유의미하게 작용함과 동시에 IL-1 수용체와 효율적으로 결합하여 인플라마솜에 의해 생성되는 IL-1β에 대한 신호 억제 효과 또한 우수함을 확인하였다. 따라서, 본 발명에 따른 융합단백질 이량체는 GLP-1과 IL-1 수용체 길항제의 효능이 복합적으로 작용하므로, 당뇨병, 비만, 고지혈증과 같은 대사성 질환의 치료 및 예방에 효과적으로 활용할 수 있어 산업적 활용 가능성이 높다.
Latest bibliographic data on file with the International Bureau